Aldeyra Therapeutics, Inc. business relationships
Companies named in Aldeyra Therapeutics, Inc.’s 10-K filed 2026-02-27, and public companies whose annual reports name Aldeyra Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 4 / 100 Top 3% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Aldeyra Therapeutics, Inc.’s annual report 2
“We currently plan to commercialize reproxalap through a collaboration with AbbVie, should AbbVie choose to exercise the AbbVie Option.” SEC filing
“Although the AbbVie Option Agreement was not considered to be a vendor-customer relationship, the Company used ASC 606 to conclude that the $ 6.0 million liability would be considered the transaction price (the Transaction Price) and all other amounts due to the Company under the Collaboration Agree...” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms